- Open Access
Unveiling transcription factor regulation and differential co-expression genes in Duchenne muscular dystrophy
© Tian et al.; licensee BioMed Central. 2014
- Received: 6 June 2014
- Accepted: 12 October 2014
- Published: 23 October 2014
Gene expression analysis is powerful for investigating the underlying mechanisms of Duchenne muscular dystrophy (DMD). Previous studies mainly neglected co-expression or transcription factor (TF) information. Here we integrated TF information into differential co-expression analysis (DCEA) to explore new understandings of DMD pathogenesis.
Using two microarray datasets from Gene Expression Omnibus (GEO) database, we firstly detected differentially expressed genes (DEGs) and pathways enriched with DEGs. Secondly, we constructed differentially regulated networks to integrate the TF-to-target information and the differential co-expression genes.
A total of 454 DEGs were detected and both KEGG pathway and ingenuity pathway analysis revealed that pathways enriched with aberrantly regulated genes are mostly involved in the immune response processes. DCEA results generated 610 pairs of DEGs regulated by at least one common TF, including 78 pairs of co-expressed DEGs. A network was constructed to illustrate their relationships and a subnetwork for DMD related molecules was constructed to show genes and TFs that may play important roles in the secondary changes of DMD. Among the DEGs which shared TFs with DMD, six genes were co-expressed with DMD, including ATP1A2, C1QB, MYOF, SAT1, TRIP10, and IFI6.
Our results may provide a new understanding of DMD and contribute potential targets for future therapeutic tests.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_210
- Duchenne muscular dystrophy
- Differential co-expression analysis
- Transcription factor
Duchenne muscular dystrophy (DMD) is a severe and progressive inherited neuromuscular disease characterized by muscle fiber degeneration and central nervous system disorders that affects 1 in 3600–6000 live male births . This disease is caused by mutations or dysregulation of the X-linked dystrophin gene. Absence of or defects of dystrophin protein result in disruption of the dystrophin-associated protein complex (DAPC), resulting in chronic inflammation and progressive muscle degeneration .
Although mutations of the DMD protein have been identified to be primarily responsible for the pathology, comprehensive understanding of the downstream mechanisms due to dystrophin absence is still lacking. Secondary changes in DMD involve calcium homeostasis , nitric oxide synthase , inflammation  and mast cell degranulation , suggesting that the pathological process of DMD is highly complicated. Gene expression profile analysis is a powerful strategy to investigate the pathophysiological mechanisms of DMD. Several gene expression profiling studies - have been performed earlier, providing insights into the pathology of DMD. However, most of them focused on expression level changes of individual genes, without considering the differences in gene interconnections. Since the majority of proteins function with other proteins, differential co-expression analysis (DCEA) would provide a better understanding of the mechanism underlying DMD progression. The rationale of DCEA is that changes in gene co-expression patterns between two disease statuses (case and control) provide hints regarding the disrupted regulatory relationships in patients. Therefore, integrate the information of Transcription factors (TFs) into DCEA may detect the regulatory causes of observed co-expression changes since TFs can regulate gene expression through binding the cis-elements in the target genes’ promoter regions. TFs are reported to be important in both normal and disease states . Investigation of TF activities in mdx mice has proposed several TFs involved in DMD pathogenesis . Thus, integrative analysis of TFs and target differential co-expression genes may provide better understanding on molecular mechanism of the secondary changes of DMD.
In this study, using microarray gene expression data collected from the Gene Expression Omnibus (GEO) database, we carried out an integrative bioinformatics analysis. Firstly, differentially expressed genes (DEGs) were detected and pathways enriched with DEGs were acquired. Secondly, differentially regulated link networks were constructed to integrate the TF-to-target information and the differential co-expression genes. Our results may provide new understanding of DMD and new targets for future therapeutic tests.
We used two datasets (GSE6011 and GSE3307) from the GEO (http://www.ncbi.nlm.nih.gov/geo/) database. For further combined analysis, we only selected samples generated with the platform GPL96: [HG-U133A] Affymetrix Human Genome U133A Array.
Detection of differentially expressed genes (DEGs)
Raw data including simple omnibus format in text (SOFT) family files and CEL files of all samples were downloaded. The CEL files contained the expression information for each probe. Robust Multiarray Analysis (RMA)  was used for raw intensity values normalization: firstly, background noise and processing artifacts were neutralized by model-based background correction; secondly, expression values were set to a common scale by quantile normalization; thirdly, expression value of each probe was generated by an iterative median polishing procedure. The resulting log2-transformed RMA expression value was then used for detecting DEGs. Statistical t test was used to identify DEGs and the Benjamini and Hochberg procedure  were carried out to correct the multiple testing problems. The threshold of significant DEGs was set as P <0.01. Up- or down-regulation of the DEGs were determined according to the fold-change. All of the above procedures were performed using the R software (v3.0.3) with BioConductor and limma packages (3.12.1) and libraries .
Differentially expressed probes were annotated based on the SOFT files. All genes were then mapped to the Kyoto En-cyclopedia of Genes and Genomes (KEGG) pathways (http://www.genome.jp/kegg/) database. The hyper geometric distribution test was used to identify pathways significantly enriched with DEGs. In addition to KEGG pathway analysis, DEGs were also uploaded into the Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems, http://www.ingenuity.com) and was associated with the canonical pathways, molecular and cellular functions, diseases and disorders in the Ingenuity Knowledge Base. Fisher’s exact test was implemented to assess the significance of the associations between DEGs and canonical pathways, functions, or diseases. For canonical pathways, a ratio was also computed between the number of DEGs and the total number of molecules in the pathway.
DCEA and TF-to-target analysis
The DEGs were subjected to DCEA and TF-to-target analysis using the DCGL package (v2.0)  in the R software. Human TF-to-target library was incorporated into the package to identify differentially regulated genes and links. A total of 215 human TFs and 16,863 targets were included in the package. Differentially co-expressed genes (DCGs) were firstly identified and a network was constructed with DCGs and their shared TFs. Since dysregulation of DMD gene is the primary cause of the disease, we also constructed a subnetwork surrounding the predefined gene DMD.
KEGG pathways enriched with differentially expressed genes
Systemic lupus erythematosus
Cell adhesion molecules (CAMs)
Signaling Molecules and Interaction
Pathogenic Escherichia coli infection
Intestinal immune network for IgA production
Antigen processing and presentation
Ingenuity pathway analysis: diseases and functions related to differentially expressed genes
Diseases and Disorders
Skeletal and muscular disorders
Molecular and Cellular functions
Cellular growth and proliferation
Cell death and survival
Cellular assembly and organization
The pathophysiology of DMD is highly complex, involving the dysregulation of many downstream cascades. Gene expression profiling is powerful for investigating the secondary changes of DMD patients. However, previous studies mainly focused on individual gene expression changes, without considering the gene co-expression pattern or the TF information. In this study, with combined two DMD microarray datasets, we implemented DCEA and constructed a TF regulated network with the hope to provide new understanding of the pathogenesis.
Both KEGG pathway and IPA canonical pathway analysis of the DEGs revealed that pathways enriched with aberrantly regulated genes are mostly involved in the immune response processes. This may be due to the infiltration of immune cells into the muscles and the elevated levels of various inflammatory cytokines -. In addition, the calcium signaling and nNOS signaling in skeletal muscle cells pathway were found to be enriched with deregulated genes, which is consistent with previous findings ,.
DCEA results generated 610 pairs of DEGs regulated by at least one common TF, including 78 pairs of co-expressed DEGs. As shown in Figure 2, many TFs are involved in the regulation of these DEGs. Since DMD is the causative gene, a subnetwork was constructed to illustrate important genes and TFs that may play important roles in the secondary changes of DMD patients (Figure 3). Among the DEGs which shared TFs with DMD, six genes were co-expressed with DMD, including ATP1A2, C1QB, MYOF, SAT1, TRIP10, and IFI6. Among them, ATP1A2, MYOF, and SAT1 have previously been reported to be involved in muscular dystrophy -. The relationship between the three left genes and DMD is still known. However, it is worth further investigation. Take IFI6 for example, this gene was highly expressed in muscle and bone and it is reported to inhibit cytochrome c release from mitochondria by regulating the Ca2+ channel which consequently attenuate apoptosis . Alterations in intracellular Ca2+ homeostasis are involved in the alteration of apoptosis since a sustained increase in cytosolic Ca2+concentration accompanies with apoptosis in cells . Previous study  have demonstrated the high influx of extracellular calcium through a dystrophin-deficient membrane, which may lead to subsequent muscle necrosis or apoptosis along with the inflammation response. Whether this gene contributes to the pathogenesis through its regulation of the Ca2+ channel needs further investigation. Among the TFs detected in the array, several TFs of DMD are dysregulated, including GATA2 and STAT5B. Further studies are needed to investigate their involvement in the disease and the mechanisms of other unmeasured TFs (Figure 3).
The ultimate cure for DMD will lie in the stable introduction of a functional dystrophin gene into the muscles of DMD patients, however, when gene therapy or transplantation of stem cells/ muscle precursor cells will be clinically available is unpredictable. In the interim, reducing secondary features of the pathologic progression of dystrophin deficiency could improve the quality and length of life for DMD patients. Dysregulation of the genes which were co-expressed with DMD may be caused by the malfunction of DMD. Therapeutic strategies aimed to compensate for the dysregulation of these genes may help to reduce the secondary features of DMD. Therefore, genes co-expressed with DMD we identified here may be considered as therapeutic targets in further investigations to treat the secondary effects. In addition, TFs that regulated these genes and DMD may also serve as potential therapeutic markers in future studies.
In summary, with combined microarray data from the GEO database, we conducted DECA and acquire the TF information of co-expressed DEGs to capture pathogenic characteristics of DMD. Our results may provide a new understanding of DMD and further contribute potential targets for future therapeutic tests.
This study is supported by the Planning program of Xuzhou Science and Technology Bureau in Jiangsu, China (Y3014).
- Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, Poysky J, Shapiro F, Tomezsko J, Constantin C: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010, 9: 77-93. 10.1016/S1474-4422(09)70271-6.PubMedView ArticleGoogle Scholar
- Hoffman EP, Brown RH, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987, 51: 919-928. 10.1016/0092-8674(87)90579-4.PubMedView ArticleGoogle Scholar
- Head SI: Branched fibres in old dystrophic mdx muscle are associated with mechanical weakening of the sarcolemma, abnormal Ca2+ transients and a breakdown of Ca2+ homeostasis during fatigue. Exp Physiol. 2010, 95: 641-656. 10.1113/expphysiol.2009.052019.PubMedView ArticleGoogle Scholar
- Altamirano F, Lopez JR, Henriquez C, Molinski T, Allen PD, Jaimovich E: Increased resting intracellular calcium modulates NF-kappaB-dependent inducible nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes. J Biol Chem. 2012, 287: 20876-20887. 10.1074/jbc.M112.344929.PubMedPubMed CentralView ArticleGoogle Scholar
- Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G: Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 2003, 60: 993-997. 10.1212/01.WNL.0000049913.27181.51.PubMedView ArticleGoogle Scholar
- Gorospe JR, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP: A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci. 1994, 122: 44-56. 10.1016/0022-510X(94)90050-7.PubMedView ArticleGoogle Scholar
- Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, Shi R, Hoffman EP: Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology. 2005, 65: 826-834. 10.1212/01.wnl.0000173836.09176.c4.PubMedView ArticleGoogle Scholar
- Haslett JN, Sanoudou D, Kho AT, Bennett RR, Greenberg SA, Kohane IS, Beggs AH, Kunkel LM: Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A. 2002, 99: 15000-15005. 10.1073/pnas.192571199.PubMedPubMed CentralView ArticleGoogle Scholar
- Pescatori M, Broccolini A, Minetti C, Bertini E, Bruno C, D'Amico A, Bernardini C, Mirabella M, Silvestri G, Giglio V, Modoni A, Pedemonte M, Tasca G, Galluzzi G, Mercuri E, Tonali PA, Ricci E: Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J. 2007, 21: 1210-1226. 10.1096/fj.06-7285com.PubMedView ArticleGoogle Scholar
- Chen YW, Zhao P, Borup R, Hoffman EP: Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 2000, 151: 1321-1336. 10.1083/jcb.151.6.1321.PubMedPubMed CentralView ArticleGoogle Scholar
- Wong B, Gilbert DL, Walker WL, Liao IH, Lit L, Stamova B, Jickling G, Apperson M, Sharp FR: Gene expression in blood of subjects with Duchenne muscular dystrophy. Neurogenetics. 2009, 10: 117-125. 10.1007/s10048-008-0167-8.PubMedView ArticleGoogle Scholar
- Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM: A census of human transcription factors: function, expression and evolution. Nat Rev Genet. 2009, 10: 252-263. 10.1038/nrg2538.PubMedView ArticleGoogle Scholar
- Dogra C, Srivastava DS, Kumar A: Protein-DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice. Mol Cell Biochem. 2008, 312: 17-24. 10.1007/s11010-008-9716-6.PubMedPubMed CentralView ArticleGoogle Scholar
- Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003, 4: 249-264. 10.1093/biostatistics/4.2.249.PubMedView ArticleGoogle Scholar
- Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol. 1995, 57: 289-300.Google Scholar
- Smyth GK, Michaud J, Scott HS: Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005, 21: 2067-2075. 10.1093/bioinformatics/bti270.PubMedView ArticleGoogle Scholar
- Yang J, Yu H, Liu BH, Zhao Z, Liu L, Ma LX, Li YX, Li YY: DCGL v2.0: an R package for unveiling differential regulation from differential co-expression. PLoS One. 2013, 8: e79729-10.1371/journal.pone.0079729.PubMedPubMed CentralView ArticleGoogle Scholar
- Spencer MJ, Walsh CM, Dorshkind KA, Rodriguez EM, Tidball JG: Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J Clin Invest. 1997, 99: 2745-2751. 10.1172/JCI119464.PubMedPubMed CentralView ArticleGoogle Scholar
- McDouall RM, Dunn MJ, Dubowitz V: Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci. 1990, 99: 199-217. 10.1016/0022-510X(90)90156-H.PubMedView ArticleGoogle Scholar
- Cai B, Spencer MJ, Nakamura G, Tseng-Ong L, Tidball JG: Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol. 2000, 156: 1789-1796. 10.1016/S0002-9440(10)65050-X.PubMedPubMed CentralView ArticleGoogle Scholar
- An HB, Zheng HC, Zhang L, Ma L, Liu ZY: Partial least squares based identification of Duchenne muscular dystrophy specific genes. J Zhejiang Univ Sci B. 2013, 14: 973-982. 10.1631/jzus.B1300060.PubMedPubMed CentralView ArticleGoogle Scholar
- Burr AR, Millay DP, Goonasekera SA, Park KH, Sargent MA, Collins J, Altamirano F, Philipson KD, Allen PD, Ma J, Lopez JR, Molkentin JD: Na + dysregulation coupled with Ca2+ entry through NCX1 promotes muscular dystrophy in mice. Mol Cell Biol. 2014, 34: 1991-2002. 10.1128/MCB.00339-14.PubMedPubMed CentralView ArticleGoogle Scholar
- Davis DB, Delmonte AJ, Ly CT, McNally EM: Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum Mol Genet. 2000, 9: 217-226. 10.1093/hmg/9.2.217.PubMedView ArticleGoogle Scholar
- Cheriyath V, Glaser KB, Waring JF, Baz R, Hussein MA, Borden EC: G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest. 2007, 117: 3107-3117. 10.1172/JCI31122.PubMedPubMed CentralView ArticleGoogle Scholar
- Cerella C, D’Alessio M, De Nicola M, Magrini A, Bergamaschi A, Ghibelli L: Cytosolic and endoplasmic reticulum Ca2+ concentrations determine the extent and the morphological type of apoptosis, respectively. Ann N Y Acad Sci. 2003, 1010: 74-77. 10.1196/annals.1299.011.PubMedView ArticleGoogle Scholar
- Blake DJ, Weir A, Newey SE, Davies KE: Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002, 82: 291-329.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.